Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms:
VAP-1-IN-2
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | VAP-1-IN-2 is an orally active VAP-1 inhibitor, with an IC50 value of 0.025 μM for humans and 0.015 μM for rats. It reduces urinary protein excretion and the progression of proteinuria in diabetic rats. VAP-1-IN-2 inhibits VAP-1 activity in rats and is applicable in research related to diabetes and kidney disease. |
| In vitro | VAP-1-IN-2 (Compound 1/17hd) is a potent inhibitor of recombinant human VAP-1, with an IC50 of 0.025 μM, and also effectively inhibits recombinant rat VAP-1, with an IC50 of 0.015 μM. |
| In vivo | VAP-1-IN-2, administered orally at doses of 0.3-1 mg/kg as a single treatment, is capable of inhibiting VAP-1 activity in rats. Additionally, VAP-1-IN-2, given orally at 0.3-1 mg/kg once daily for 4 weeks, significantly reduces the progression of proteinuria and plasma VAP-1 activity in rats with Streptozotocin-induced diabetes. |
| Molecular Weight | 494.97 |
| Formula | C25H27ClN6O3 |
| Cas No. | 1279026-89-9 |
| Smiles | O=C(O)C1=CC=C(C(Cl)=C1)N2CCN(C=3N=CC(=CN3)C4=CC=CC(=C4)CN(C(=O)CN)C)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.